دورية أكاديمية
Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease.
| العنوان: | Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease. |
|---|---|
| المؤلفون: | Domech CR; National Institute of Gastroenterology, Cuba., Travieso JCF; National Centre for Scientific Research, Cuba., Guridi ZD; National Institute of Gastroenterology, Cuba., Fernández MIC; National Institute of Gastroenterology, Cuba., Del Vallín SL; National Institute of Gastroenterology, Cuba., Carralero AR; National Institute of Gastroenterology, Cuba., Batallie EF; National Institute of Gastroenterology, Cuba., Alvarez AMA; National Institute of Endocrinology, Cuba., Dorta LF; National Centre for Scientific Research, Cuba., Ferrer JI; National Centre for Scientific Research, Cuba., Castaño SM; National Centre for Scientific Research, Cuba., García MR; National Coordinator Centre for Clinical Trials, Cuba., Rivero GJ; National Coordinator Centre for Clinical Trials, Cuba., Alvarez YV; National Coordinator Centre for Clinical Trials, Cuba. |
| المصدر: | Clinical and experimental hepatology [Clin Exp Hepatol] 2021 Mar; Vol. 7 (1), pp. 55-65. Date of Electronic Publication: 2021 Mar 12. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Termedia Publishing House Country of Publication: Poland NLM ID: 101703431 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2392-1099 (Print) Linking ISSN: 23921099 NLM ISO Abbreviation: Clin Exp Hepatol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Poznań : Termedia Publishing House : [2015]- |
| مستخلص: | Aim of the Study: To investigate the efficacy and safety of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease (NAFLD).Material and methods: The present study had a monocentric, randomized, double-blinded, comparative design with 4 parallel groups - group 1 (Abexol), group 2 (atorvastatin), group 3 (combined therapy) and group 4 (placebo) - to which dietary recommendations and physical activity practice were provided twice a day, for 24 weeks. Significant changes in the ultrasound analysis of the liver were considered a primary efficacy variable. Insulin resistance improvement (HOMA2-IR) was considered as a co-primary efficacy criterion. Significant changes in the serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), lipid profile variables and the anthropometric variables were evaluated as secondary variables of effectiveness. Statistical analysis of all data was according to the intention to treat method. Results: The groups were statistically homogeneous at baseline conditions. At the end of the 6 months of treatment about 50% of the patients in all groups showed a decrease of at least one degree in echogenicity, while the rest remained the same. There were no significant changes in the values of liver enzymes or anthropometric variables evaluated. Treatment with atorvastatin and combined therapy significantly reduced levels of low-density lipoprotein-cholesterol (LDL-C) and total cholesterol. The treatments were safe and well tolerated, although in the atorvastatin group the number of adverse events reported was greater than in the rest of the groups. Conclusions: Abexol and atorvastatin showed comparable efficacy and safety in patients with NAFLD, with advantages for treatment with atorvastatin with respect to its effects on the lipid profile of these patients. Competing Interests: The authors declare no conflict of interest. (Copyright © 2021 Clinical and Experimental Hepatology.) |
| References: | Prim Care. 2017 Dec;44(4):599-607. (PMID: 29132522) Ann Gastroenterol. 2018 May-Jun;31(3):288-295. (PMID: 29720854) Hepatology. 2016 Jun;63(6):1875-87. (PMID: 26849287) World J Hepatol. 2018 Aug 27;10(8):530-542. (PMID: 30190781) Prostaglandins Leukot Essent Fatty Acids. 1998 Oct;59(4):235-8. (PMID: 9849648) Korean J Intern Med. 2013 Jul;28(4):439-48. (PMID: 23864802) Int J Biol Sci. 2019 Jan 1;15(2):265-276. (PMID: 30745819) Gastroenterol Hepatol (N Y). 2020 Mar;16(3):119-130. (PMID: 34035711) J Pharm Pharmacol. 1996 Aug;48(8):858-60. (PMID: 8887738) Clin Exp Hepatol. 2018 Sep;4(3):165-174. (PMID: 30324141) Int J Mol Sci. 2019 Apr 20;20(8):. (PMID: 31010049) Gastroenterology. 2012 Jun;142(7):1592-609. (PMID: 22656328) J Med Food. 2001 Summer;4(2):71-77. (PMID: 12639415) Hepatobiliary Surg Nutr. 2019 Apr;8(2):167-169. (PMID: 31098370) Clin Pharmacol Ther. 1981 Aug;30(2):239-45. (PMID: 7249508) J Hepatol. 2020 Sep;73(3):680-693. (PMID: 32353483) J Med Food. 2001 Summer;4(2):79-83. (PMID: 12639416) Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1103-1115. (PMID: 30113367) Clin Liver Dis (Hoboken). 2018 Apr;11(4):98-104. (PMID: 30147867) Trends Endocrinol Metab. 2019 Oct;30(10):701-709. (PMID: 31422872) Braz J Med Biol Res. 2000 Jan;33(1):85-90. (PMID: 10625879) Clin Chem. 1972 Jun;18(6):499-502. (PMID: 4337382) Pharm Pract (Granada). 2016 Jan-Mar;14(1):708. (PMID: 27011778) J Med Food. 2005 Spring;8(1):63-8. (PMID: 15857212) Curr Pharm Des. 2018;24(38):4587-4592. (PMID: 30652643) Hepatol Commun. 2018 Jun 07;2(7):778-785. (PMID: 30027137) World J Hepatol. 2017 Jun 8;9(16):715-732. (PMID: 28652891) World J Gastroenterol. 2018 Aug 14;24(30):3361-3373. (PMID: 30122876) Gene Expr. 2018 May 18;18(2):89-101. (PMID: 29212576) Arch Med Res. 2001 Sep-Oct;32(5):436-41. (PMID: 11578760) Clin Mol Hepatol. 2019 Mar;25(1):1-11. (PMID: 30086613) |
| فهرسة مساهمة: | Keywords: Abexol; HOMA index; atorvastatin; liver echogenicity; non-alcoholic fatty deposition liver disease |
| تواريخ الأحداث: | Date Created: 20210524 Latest Revision: 20240402 |
| رمز التحديث: | 20240402 |
| مُعرف محوري في PubMed: | PMC8122099 |
| DOI: | 10.5114/ceh.2021.104387 |
| PMID: | 34027116 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2392-1099 |
|---|---|
| DOI: | 10.5114/ceh.2021.104387 |